TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
52.03
-1.50 (-2.80%)
At close: Jul 31, 2026, 4:00 PM EDT
51.80
-0.23 (-0.44%)
After-hours: Jul 31, 2026, 7:59 PM EDT
TG Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 442.21 | 79.15 | 179.89 | 92.93 | 102.3 | 298.89 |
Short-Term Investments | 72.22 | 62.82 | 131.11 | 124.58 | 59.37 | 15.88 |
Cash & Short-Term Investments | 514.43 | 141.97 | 311 | 217.51 | 161.68 | 314.76 |
Cash Growth | 86.23% | -54.35% | 42.98% | 34.53% | -48.63% | -48.01% |
Accounts Receivable | 392.05 | 305.63 | 129.19 | 51.09 | - | 1.39 |
Inventory | 129.03 | 125.59 | 110.46 | 39.82 | - | - |
Other Current Assets | 51.46 | 57.58 | 15.72 | 9.52 | 6.6 | 14.81 |
Total Current Assets | 1,087 | 630.76 | 566.36 | 317.94 | 168.27 | 330.97 |
Net Property, Plant & Equipment | 6.48 | 6.28 | 7.15 | 8.05 | 10.82 | 11.07 |
Goodwill | - | - | - | - | 0.8 | 0.8 |
Long-Term Investments | 61.54 | 59.14 | 0.81 | - | 12.4 | 35.53 |
Other Long-Term Assets | 373.85 | 367.08 | 3.37 | 3.59 | 1.27 | 1.26 |
Total Assets | 1,529 | 1,063 | 577.69 | 329.59 | 193.57 | 379.63 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 148.85 | 107.51 | 58.3 | 38.47 | 42.02 | 51.29 |
Accrued Expenses | 18.66 | 21.85 | 15.19 | 12.17 | 8.43 | 10.17 |
Current Portion of Long-Term Debt | - | - | - | - | - | 0.98 |
Current Portion of Leases | 1.82 | 1.04 | 1.16 | 1.45 | 1.58 | 1.44 |
Unearned Revenue | 17.19 | 21.23 | 11.41 | 0.15 | - | - |
Other Current Liabilities | 0.6 | 2.12 | 4.63 | 1.48 | 1.17 | 1.51 |
Total Current Liabilities | 187.11 | 153.76 | 90.68 | 53.72 | 53.2 | 65.38 |
Long-Term Debt | 745.14 | 245.65 | 244.43 | 100.12 | 71.14 | 66.79 |
Long-Term Leases | 6.6 | 7.02 | 8.13 | 9.23 | 10.34 | 9.85 |
Other Long-Term Liabilities | 6.86 | 8.81 | 12.09 | 6.02 | 0.31 | 0.46 |
Total Long-Term Liabilities | 758.6 | 261.47 | 264.65 | 115.37 | 81.78 | 77.09 |
Total Liabilities | 945.71 | 415.23 | 355.33 | 169.09 | 134.99 | 142.48 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.16 | 0.16 | 0.16 | 0.15 | 0.15 | 0.14 |
Treasury Stock | -200.23 | -100.23 | -8.99 | -0.23 | -0.23 | -0.23 |
Additional Paid-in Capital | 1,845 | 1,830 | 1,760 | 1,713 | 1,586 | 1,566 |
Retained Earnings | -1,062 | -1,082 | -1,529 | -1,553 | -1,527 | -1,329 |
Shareholders' Equity | 583.13 | 648.02 | 222.36 | 160.5 | 58.59 | 237.15 |
Total Liabilities & Equity | 1,529 | 1,063 | 577.69 | 329.59 | 193.57 | 379.63 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 753.56 | 253.71 | 253.72 | 110.8 | 83.06 | 79.05 |
Net Cash (Debt) | -239.13 | -111.74 | 57.28 | 106.71 | 78.62 | 235.72 |
Net Cash Growth | - | - | -46.32% | 35.74% | -66.65% | -58.17% |
Net Cash Per Share | -1.49 | -0.69 | 0.36 | 0.72 | 0.58 | 1.78 |
Book Value | 583.13 | 648.02 | 222.36 | 160.5 | 58.59 | 237.15 |
Book Value Per Share | 3.63 | 4.01 | 1.39 | 1.08 | 0.43 | 1.79 |
Tangible Book Value | 583.13 | 648.02 | 222.36 | 160.5 | 57.79 | 236.35 |
Tangible Book Value Per Share | 3.63 | 4.01 | 1.39 | 1.08 | 0.43 | 1.79 |